Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects (2C-B)

This RCT (n=24) does a direct comparison, the first one in a double-blind trial, of MDMA, psilocybin, and 2C-B (a novel psychedelic with MDMA & psilocybin-like effects). Next to a placebo, the dosages of MDMA (125mg) and psilocybin (25mg) are high, whilst that of 2C-B will be a variety of doses (10, 20, 30mg). All participants will receive all compounds and a placebo (cross-over study design).

Trial Details

2-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic substance psilocybin (contained in "magic, hallucinogenic mushrooms"). Pharmacologically, MDMA mainly releases serotonin (5-HT) via the serotonin transporter (SERT) and psilocybin mainly acts as direct agonist at 5-HT2A receptors. 2C-B interacts with both the 5-HT2A receptor and SERT which is in line with its reported mixed effects profile. However, scientific studies are lacking. There is an increased interest in psychiatric research on the therapeutic properties of MDMA and psilocybin and also on mixed empathogenic-psychedelic substances.

NCT Number NCT05523401

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.